190 related articles for article (PubMed ID: 30484708)
1. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
[No Abstract] [Full Text] [Related]
2. High-dose chemotherapy for triple negative breast cancer.
De Giorgi U; Rosti G; Frassineti L; Kopf B; Giovannini N; Zumaglini F; Marangolo M
Ann Oncol; 2007 Jan; 18(1):202-203. PubMed ID: 16971660
[No Abstract] [Full Text] [Related]
3. Different subtypes of metaplastic breast cancer might have different sensitivity to neoadjuvant chemotherapy.
Altundag K
J BUON; 2019; 24(5):2205. PubMed ID: 31786895
[No Abstract] [Full Text] [Related]
4. Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
Ottestad L; Fronth L; Rajendiran S; Hege Aksnes L; Eikesdal HP; Støre Blix E; Ewertz M
Acta Oncol; 2019 Mar; 58(3):385-387. PubMed ID: 30798641
[No Abstract] [Full Text] [Related]
5. Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression.
Wu D; Tang S; Ye R; Li D; Gu D; Chen R; Zhang H; Sun J; Chen Z
Front Immunol; 2021; 12():610149. PubMed ID: 33692787
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
[TBL] [Abstract][Full Text] [Related]
8. Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.
Del Mastro L; Cazzaniga M; Solidoro P; Generali D; Bianchi G; Testore F; De Placido S
Future Oncol; 2015; 11(16):2251-4. PubMed ID: 26260802
[No Abstract] [Full Text] [Related]
9. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
Abramovitz M; Williams C; Loibl S; Leyland-Jones B
Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
[TBL] [Abstract][Full Text] [Related]
10. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
12. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
13. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Blackwell K; Burris H; Gomez P; Lynn Henry N; Isakoff S; Campana F; Gao L; Jiang J; Macé S; Tolaney SM
Breast Cancer Res Treat; 2015 Nov; 154(2):287-97. PubMed ID: 26497877
[TBL] [Abstract][Full Text] [Related]
15. [Association of estrogen and progesterone receptor levels and the expected response to chemotherapy and hormone therapy in breast carcinoma with increased expression of human epidermal growth factor 2].
Susnjar S; Nesković-Konstantinović Z; Stamatović L; Vasović S; Strabic M; Nikolić-Vukosavljević D; Jovanović D
Srp Arh Celok Lek; 2003; 131(11-12):443-8. PubMed ID: 15114785
[TBL] [Abstract][Full Text] [Related]
16. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
17. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Burstein HJ; Lacchetti C; Griggs JJ
J Oncol Pract; 2019 Feb; 15(2):106-107. PubMed ID: 30523754
[No Abstract] [Full Text] [Related]
19. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
20. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
Mehta RS
J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
[No Abstract] [Full Text] [Related]
[Next] [New Search]